Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
581 studies found for:    B-CELL CLL/LYMPHOMA 2
Show Display Options
Rank Status Study
1 Recruiting Validation of Useful Markers Generated by Next Generation Bio-data Based Genome Research and Cohort Study
Condition: BCL2 Gene mRNA Overexpression
Intervention:
2 Terminated R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma
Conditions: Chronic Lymphocytic Leukaemia;   Small Lymphocytic Lymphoma
Interventions: Drug: Rituximab;   Drug: Cladribine
3 Completed
Has Results
A Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (RESONATE™-2)
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Chlorambucil
4 Active, not recruiting
Has Results
A Multicenter Phase 2 Study of PCI-32765 (Ibrutinib) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion
Conditions: Chronic Lymphocytic Leukemia With 17p Deletion;   Small Lymphocytic Lymphoma With 17p Deletion
Intervention: Drug: PCI-32765
5 Withdrawn A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Non-Hodgkin Lymphoma
Interventions: Drug: Duvelisib;   Drug: Venetoclax
6 Terminated A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)
Conditions: Leukemia, Lymphocytic, Chronic, B-Cell;   Chronic Lymphocytic Leukemia;   Lymphoma, Small Lymphocytic
Intervention: Drug: Lenalidomide, Rituximab, and Cyclophosphamide
7 Terminated A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas
Conditions: Leukemia, Lymphocytic, Chronic, B-Cell;   Lymphoma, B-Cell
Intervention: Drug: AEG35156 antisense IV infusion
8 Terminated Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma
Conditions: Follicular Lymphoma;   Small Lymphocytic Lymphoma
Interventions: Drug: Idelalisib;   Biological: Rituximab
9 Recruiting A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Condition: Leukemia, Lymphocytic, Chronic, B-Cell
Interventions: Drug: CC-122;   Drug: Ibrutinib;   Drug: Obinutuzumab
10 Completed Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL)
Conditions: Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia
Intervention: Drug: CAT-8015 Immunotoxin (Moxetumomab Pasudotox)
11 Active, not recruiting Phase 2 Study of the Combination of Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients
Condition: Leukemia
Interventions: Drug: Rituximab;   Drug: PCI-32765
12 Active, not recruiting PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia
Conditions: Prolymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory/Relapsed Chronic Lymphocytic Leukemia
Interventions: Drug: ibrutinib;   Other: Correlative laboratory samples;   Other: quality of life assessment
13 Recruiting Phase I Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma
Conditions: Chronic Lymphocytic Leukaemia (CLL);   B-Cell Non-Hodgkin Lymphoma (NHL);   Multiple Myeloma (MM)
Intervention: Drug: S 55746
14 Recruiting Phase 1/2A Dose Escalation Study in CLL, SLL or NHL
Conditions: Follicular Lymphoma (FL/Indolent NHL);   Aggressive NHL (a NHL);   Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL);   T-cell Lymphoma (PTCL and CTCL);   B-cell Non Hodgkin Lymphoma (NHL)
Intervention: Drug: cerdulatinib (PRT062070)
15 Terminated SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)
Conditions: Lymphoma, Mantle-Cell;   Leukemia, Lymphocytic, Chronic, B-Cell
Interventions: Drug: SCH 727965;   Drug: Bortezomib;   Biological: Alemtuzumab
16 Recruiting Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
Conditions: Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Acute Lymphocytic Leukemia
Interventions: Biological: CD19 Specific CAR T Cells;   Biological: CD19 Specific CAR T Cells Fixed Dose
17 Terminated A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL
Conditions: Chronic Lymphocytic Leukemia (CLL);   Small Lymphocytic Lymphoma (SLL)
Interventions: Drug: Idelalisib;   Drug: Rituximab
18 Terminated FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma
Conditions: Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Small Lymphocytic Lymphoma
Interventions: Drug: romidepsin;   Biological: rituximab;   Drug: fludarabine phosphate;   Other: laboratory biomarker analysis
19 Recruiting Ibrutinib Plus Venetoclax in Patients With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma
Conditions: Leukemia, Chronic Lymphocytic;   Lymphoma, Small Lymphocytic
Interventions: Drug: ibrutinib;   Drug: placebo to match ibrutinib;   Drug: venetoclax
20 Unknown  Study of AQ4N in Patients With Non Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Leukemia
Conditions: Non-Hodgkin's Lymphoma;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Leukemia
Intervention: Drug: AQ4N (Chemotherapy)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.